Metastatic castration-resistant prostate cancer (mCRPC) is known as a cancer that more often than not metastasizes to the bone. Less often it moves to nonosseous sites (soft tissue sites like lymph nodes, liver and lung).

The last few years has seen the development of new drugs that extend the survival of men. Because of these new treatments and their relative success in extending life it has been hypothesized that the pattern of metastases is changing.

To evaluate these possible changing trends the pattern of metastatic disease was evaluated in men with mCRPC. The evaluation was prepared by looking at all phase 2 and 3 therapeutic s